Kentucky Association of Manufacturers’ Post

Kentucky Association of Manufacturers reposted this

This Wall Street Journal article highlights a critical flaw in our health care system: the enormous disparity in prescription drug prices, driven by a system where middlemen profit while American families and businesses bear the cost.⁣ ⁣ The article revealed staggering examples of drug pricing inconsistencies:⁣ ⁣ -Medicare drugs with prices that range by thousands of dollars depending on the plan and location.⁣ -Generic prostate-cancer drugs that cost $815 in one county but surge to $3,356 in another.⁣ -Seniors forced to dip into retirement savings or find part-time jobs just to afford life-saving medications.⁣ ⁣ This isn’t just an isolated issue affecting public safety nets like Medicare—it’s a broken, profit-driven system that impacts private markets too. Patients are paying more than they should while losing access to some of the care they need.⁣ ⁣ 𝐈𝐭’𝐬 𝐜𝐨𝐬𝐭𝐢𝐧𝐠 𝐮𝐬 𝐢𝐧 𝐦𝐨𝐧𝐞𝐲, 𝐚𝐜𝐜𝐞𝐬𝐬, 𝐚𝐧𝐝 𝐡𝐞𝐚𝐥𝐭𝐡—𝐚𝐧𝐝 𝐢𝐭 𝐬𝐡𝐨𝐮𝐥𝐝𝐧’𝐭 𝐛𝐞 𝐭𝐡𝐢𝐬 𝐰𝐚𝐲.⁣ ⁣ We believe there’s a better approach—one that prioritizes transparency, equitable pricing and patient care over profit margins. It's time to address this systemic dysfunction. Let's move toward a future where healthcare serves the people, not profit-first conglomerates.⁣ ⁣ What changes do you think are most urgently needed? Share your thoughts below. Article link: https://lnkd.in/gwSuKdXk

  • No alternative text description for this image
Andrew Serio

Retired: Large Group Health Plan Professional ( 1972-2022)

3mo

The "Change" thru pushing Price Transparency with the assumption that the 53% of Americans having coverage thru their employer and Medicare enrollees with AARP endorsed insurers will actually shop for their drugs based on Transparent Drug lists has not occurred. Aon & WTW just released 2025 Cost /Health Spend increase projections at 1O%. The Top 10 Brokers; WTW, Marsh, Aon, Gallagher, Alliant....etc., recommend to their Mega and Large Self-Insured Employer Clients, PBMs based on their BUCA ASO/PPO. Selling PBM separately, based on Price Transparency is not going to move the 2025 PBM Market to serve the people. The people want the Outcome they expect from seeking Medical Care from their PCP, including from the PCPs referred treatment. They know that Healthcare is a Business driven by Revenue.

Like
Reply

To view or add a comment, sign in

Explore topics